english.prescrire.org > Spotlight > Archives : 2023 > Lenacapavir (Sunlenca°) in multidrug-resistant HIV-1 infection

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Lenacapavir (Sunlenca°) in multidrug-resistant HIV-1 infection

 Marketing Authorisations   Lenacapavir is an antiretroviral drug that binds to the HIV-1 capsid. This disrupts various steps in the HIV lifecycle in which the capsid plays a role, such as transport of the viral genome into the nucleus of an infected cell, integration of the viral genome, and assembly of various viral components. It is the first antiretroviral with this mechanism of action to have been authorised in the European Union.
Full article (3 pages) available for download by subscribers

©Prescrire 1 October 2023

Source: "Lenacapavir (Sunlenca°) in multidrug-resistant HIV-1 infection" Prescrire Int 2023; 32 (252): 239-241. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Fostemsavir (RUKOBIA°)
in multidrug-resistant
HIV-1 infection"
Prescrire Int 2022;
 31 (237): 120-121.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's Spotlight